摘要
本文介绍中剂量灭吐灵、地塞米松联用时的镇吐疗效。无呕吐率67％,较文献报道的大剂量地塞米松的无呕吐率56％及大剂量灭吐灵的28％要好。治疗组与对照组相比,各反应梯次,均有非常显著差异。对DDP等强致吐药物,灭吐灵联用时,单次剂量以不少于40mg为宜。
This paper presents the study of antiemetic efficacy of combined medium dose MCP and DXM in patients with chemotherapy-induced nausea and vomiting. Complete antiemetic protection (no emesis) was achieyed in 63 of 94 patients(67%), better than those of HDDXM (56%) and HDMCP (28%) as previously reported. There was significant difference between the treated cases and contro1 group. The single dose of MCP in combined treatment should be greater than 40 mg when intense emesis- inducing drugs such as DDP is administered.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1989年第2期74-76,共3页
Chinese Journal of Clinical Oncology
